Hope on the horizon: how pegbelfermin offers a glimmer of hope for NASH sufferers?

被引：0
作者：
Mukhtiar, Sawairah [1 ]
Babar, Nisha [1 ]
Rehan, Fatima [1 ]
机构：
[1] Dow Int Med Coll, Karachi, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2023年 / 73卷 / 12期
关键词：
D O I：
10.47391/JPMA.9769
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2526 / 2527
页数：2
相关论文
共 5 条
  • [1] American College of Gastroenterology (ACG), Non-alcoholic Fatty Liver Disease (NAFLD) Overview
  • [2] Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
    Brown, Elizabeth A.
    Minnich, Anne
    Sanyal, Arun J.
    Loomba, Rohit
    Du, Shuyan
    Schwarz, John
    Ehman, Richard L.
    Karsdal, Morten
    Leeming, Diana J.
    Cizza, Giovanni
    Charles, Edgar D.
    [J]. JHEP REPORTS, 2023, 5 (04)
  • [3] Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
    Kemas, Aurino M.
    Youhanna, Sonia
    Lauschke, Volker M.
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 39 - 49
  • [4] Hepatic damage caused by long-term high cholesterol intake induces a dysfunctional restorative macrophage population in experimental NASH
    Maretti-Mira, Ana C.
    Salomon, Matthew P.
    Hsu, Angela M.
    Kanel, Gary C.
    Golden-Mason, Lucy
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
    Verzijl, Cristy R. C.
    Van de Peppel, Ivo P.
    Struik, Dicky
    Jonker, Johan W.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 125 - 133
1